Cancer diagnosis is a multistep process that combines clinical assessment, imaging, laboratory tests and, when required, examination of cells or tissue by a pathologist. The exact pathway depends on the suspected cancer, symptoms, anatomical site and whether the abnormality was detected through screening or incidentally. A clinician first obtains a history and performs an examination, looking for features that suggest a particular organ or disease process. Investigations may then include blood tests, urine tests, imaging or endoscopic procedures.
Imaging can identify a suspicious mass or abnormal area and determine its anatomical extent, but an image alone does not always establish that a lesion is malignant. For many solid cancers, a definitive diagnosis requires cytological or histological examination of material obtained from the suspicious site.
Medical history and physical examination remain important even in an era of advanced molecular diagnostics. Clinicians assess symptoms, their duration and progression, relevant exposures, previous illnesses, medications, family history and examination findings. Depending on the suspected cancer, examination may include assessment of lymph nodes, skin, breasts, abdomen, neurological function or other organ systems. These findings help determine which investigations are appropriate and can also reveal evidence of local or systemic disease. In some circumstances, a clinician may identify a lesion that requires urgent investigation even when the probability of cancer is uncertain. Diagnostic pathways are designed to investigate potentially serious causes without assuming that cancer is already present.
Imaging provides information about anatomy and disease distribution. Ultrasound is particularly useful for superficial structures and organs such as the thyroid, breast and abdomen and can distinguish fluid-filled from solid components in many circumstances. CT provides detailed cross-sectional images and is widely used to assess the chest, abdomen and pelvis and to evaluate potential spread. MRI provides excellent soft-tissue contrast and is particularly useful for the brain, spinal cord, pelvis, joints and certain tumours.
PET can identify areas of increased metabolic activity when combined with an appropriate tracer and is often integrated with CT. Imaging can guide biopsies, help determine whether surgery is feasible and contribute to staging, but inflammatory and benign processes can sometimes mimic cancer on scans.
Endoscopic examinations allow clinicians to inspect internal surfaces directly and obtain tissue. Examples include colonoscopy for the large bowel, gastroscopy for the upper digestive tract and bronchoscopy for parts of the respiratory system. During these procedures, suspicious areas can be sampled for pathological analysis. Other image-guided procedures use ultrasound, CT or another imaging modality to place a needle accurately into a lesion. Fine-needle aspiration can obtain cells for cytological examination, while core biopsy retrieves a small cylinder of tissue that preserves more architecture. The choice of sampling method depends on the lesion's location, accessibility, suspected diagnosis and information needed for treatment planning.
Blood tests can provide important supporting information but are rarely sufficient by themselves to diagnose most cancers. A full blood count may reveal anaemia or abnormal blood-cell patterns, while biochemical tests can identify changes in liver, kidney or other organ function. Some cancers release substances detectable in blood, commonly called tumour markers, including PSA, CA-125, CEA, AFP and others. However, tumour markers vary in sensitivity and specificity and can be elevated for non-cancerous reasons or remain normal despite cancer. Their uses differ substantially by tumour type and may include monitoring treatment, assessing recurrence risk or supporting diagnosis in selected contexts. A normal tumour-marker result therefore does not generally exclude cancer, and an elevated result does not automatically prove cancer.
Pathology provides the definitive classification for many cancers. A pathologist examines cells or tissue under the microscope and assesses architecture, cellular morphology, differentiation and other features. Immunohistochemistry can detect proteins that help identify the tissue lineage and distinguish among similar-looking tumours. Molecular and genetic tests can identify mutations, gene fusions, amplifications, receptor status and other alterations that may refine diagnosis or determine eligibility for targeted treatments. Modern cancer diagnosis therefore increasingly combines morphology with molecular pathology. In some cancers, molecular features are essential components of the diagnostic definition rather than optional additional information. The pathology report can consequently contain diagnosis, grade, margins, lymph-node findings, biomarkers and other features relevant to treatment and staging.
Diagnosis is distinct from staging and grading. Diagnosis identifies what disease is present, while staging determines how far a cancer has spread and grading describes certain microscopic features associated with tumour behaviour. Once cancer is diagnosed, further tests may be performed to determine the primary site, lymph-node involvement, distant metastases and molecular characteristics. Staging can involve additional imaging, surgical findings or pathology. Treatment decisions are then based on the integrated diagnostic picture rather than on the initial biopsy result alone. Multidisciplinary teams may include pathologists, radiologists, surgeons, oncologists and specialist nurses who review the findings together, particularly for complex cases.
There is no single universal cancer diagnostic test. Different cancers require different combinations of investigations, and some suspicious findings ultimately prove to be benign or non-cancerous. Screening is also distinct from diagnosis: screening tests are applied to people without symptoms who belong to a population for which evidence supports screening, whereas diagnostic testing investigates symptoms or abnormal findings. Screening can identify cancers or precancerous changes earlier but can also generate false-positive results requiring further investigation. Conversely, false-negative results can occur. The diagnostic process therefore involves interpreting test results in context and, when necessary, obtaining tissue confirmation. Accurate diagnosis is essential because cancers that appear similar anatomically may have very different biological characteristics and require different treatments.
